Bangkok OncoServ บางกอก ออนโคเสิร์ฟ

Personalized Cancer Medicine

ไทย | English

Cancer Cell Profiling is personalized medicine. Currently, there are over 50 chemotherapeutic agents and hundreds of potential drug combinations available for cancer treatment. Furthermore, cancer is a heterogeneous disease which makes each patient's response to treatment different. Cancer Cell Profiling uses each patient's own cancer cells to determine the best treatment option for him or her. The results of our tests can be used to assist physicians in making each patient's care and management plan.

To quote Sun Tzu in The Art of War: “So it is said that if you know your enemies and know yourself, you will not be imperiled in a hundred battles; if you do not know your enemies but do know yourself, you will win one and lose one; if you do not know your enemies nor yourself, you will be imperiled in every single battle”.

Survival Curve

Prediction of carboplatin resistant in ovarian cancer
Kaplan-Meier survival curves of patients with moderate to poorly-differentiated ovarian cancer. Each patient's cancer cells were exposed to carboplatin in our test system. In this prospective study, our tests showed that assay-sensitive patients had longer survival than assay-resistant (median survival = 1082 days) or assay-intermediate (median survival = 1166 days) patients. Median survival for assay-sensitive patients had not yet been reached at the time this study was reported.

Yet, cancer is not an “enemy” that everyone can beat. However, if we know as much about each patient's disease as possible, the chance of survival will increase tremendously. The result of our tests does not guarantee that a drug or drug combination will work for a patient, but it increases his or her chance of treatment success, which can be either an increase in survival or an improvement of his or her quality of life.

Visualization of cancer cells after exposure to anti-cancer drugs.

Clusters of ovarian cancer cells were cultured in the presence of absence of anti-cancer drugs. At the end of the incubation period, this patient's cancer cells showed resistance to Doxil treatment, but were sensitive to Topotecan.